Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Therapy

New bone-sparing thiazolidinedione

Nature Reviews Endocrinology volume 10, page 702 (2014)Cite this article

Subjects

Access through your institution
Buy or subscribe

Thiazolidinediones have several adverse effects, including an increased risk of fracture. This effect is thought to be related to the activation of PPARγ, which decreases osteoblast formation and increases osteoclast formation. A new thiazolidinedione analogue, MSDC-0602, has insulin-sensitizing properties but low affinity for PPARγ. Fukunaga and colleagues tested the effects of the new drug on bone and saw that MSDC-0602 did not increase osteoclast differentiation and proliferation in cells in culture and in live mice, in contrast with rosiglitazone.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Fukunaga, T. et al. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss. J. Bone Miner. Res. 10.1002/jbmr.2364

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

New bone-sparing thiazolidinedione. Nat Rev Endocrinol 10, 702 (2014). https://doi.org/10.1038/nrendo.2014.180

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrendo.2014.180

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing